In a trial that tested an anti–PD-1 antibody, nivolumab, in patients with kidney cancer (Choueiri cohort; ref. 38), the CCL22- and TNFSF10-based score differentiated the response at an AUC of 75% (Fig. 4B). Here, TNFSF10 is linked to kidney cancer.